Since the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins. Applicability and safety of this technology have been proven by use of various PEGylated pharmaceuticals for many years. It is expected that PEGylation, as the most established technology for extension of drug residence in the body, will play an important role in the next generation therapeutics, such as peptides, protein nanobodies and scaffolds, which due to their diminished molecular size need half-life extension. This review focuses on several factors important in the production of PEGylated biopharmaceuticals enabling efficient preparation of highly purified PEG-protein conjugates that have to meet stringent regulatory criteria for their use in human therapy. Areas addressed are PEG properties, the specificity of PEGylation reactions, separation and large-scale purification, the availability and analysis of PEG reagents, analysis of PEG-protein conjugates, the consistency of products and processes and approaches used for rapid screening of pharmacokinetic properties of PEG-protein conjugates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/biot.200900218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim.
Drugs R D
June 2024
Coherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Background: Pegfilgrastim-cbqv/CHS-1701 (UDENYCA) (hereafter referred to as pegfilgrastim-cbqv) was approved in 2018 by the US Food and Drug Administration as a biosimilar for pegfilgrastim (Neulasta) (hereafter referred to as pegfilgrastim). Both pegfilgrastim-cbqv and pegfilgrastim are conjugates of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF) with a 20 kDa polyethylene glycol (PEG) indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive anticancer drugs. The demonstration of analytical similarity for PEG-protein conjugates presents unique challenges since both the protein and PEG attributes must be characterized.
View Article and Find Full Text PDFHydrodynamic and thermodynamic analysis of PEGylated human serum albumin.
Biophys J
August 2024
Department of Chemistry and Biochemistry, University of Toledo, Toledo, Ohio.
Covalent labeling of therapeutic drugs and proteins with polyethylene glycol (PEGylation) is an important modification for improving stability, solubility, and half-life. PEGylation alters protein solution behavior through its impact on thermodynamic nonideality by increasing the excluded volume, and on hydrodynamic nonideality by increasing the frictional drag. To understand PEGylation's impact, we investigated the thermodynamic and hydrodynamic properties of a model system consisting of PEGylated human serum albumin derivatives using analytical ultracentrifugation (AUC) and dynamic light scattering (DLS).
View Article and Find Full Text PDFAnalytical chromatography approaches during the synthesis and conjugation of methoxypolyethylene glycol-succinimidyl butanoate (mPEG-SBA) to epoetin beta.
J Chromatogr B Analyt Technol Biomed Life Sci
April 2023
Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran; AryaTinaGene Biopharmaceutical Company, Gorgan, Iran. Electronic address:
Conjugation of epoetin beta (EPO) with methoxypolyethylene glycol-succinimidyl butanoate (mPEG-SBA) was studied. The compound mPEG-SBA was synthesized from mPEG, and the obtained intermediates and final product were analyzed by a reversed-phase chromatographic system equipped with an evaporative light scattering detector. Labeling the hydroxyl group in PEGs with benzoyl chloride and succinimide with benzylamine was applied to resolve and characterize different PEGs.
View Article and Find Full Text PDFDesign and Study of PEG Linkers That Enable Robust Characterization of PEGylated Proteins.
ACS Pharmacol Transl Sci
August 2021
Process Research and Development, Merck & Co. Inc., 126 E. Lincoln Ave, Rahway, New Jersey 07065, United States.
Several PEGylated therapeutic proteins are approved drugs, and more are under development. However, the synthesis and characterization of these bioconjugates, especially heterogeneous mixtures of PEGylated proteins, are challenging. The present study focuses on the development of PEG linkers that can be installed through biocatalytic route and render much simpler and insightful analytical characterization of PEG-protein conjugates.
View Article and Find Full Text PDFA generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum.
J Immunol Methods
November 2019
Biologics Development Sciences, Janssen BioTherapeutics, Janssen R&D, LLC, 1400 McKean Road, PO Box 776, Spring House, PA 19477, USA.
Article Synopsis
- The detection of anti-drug antibodies (ADAs) is crucial in developing large molecule biopharmaceuticals, particularly for complex forms like fusion proteins and PEGylated proteins.
- The study introduces a novel ELISA method specifically designed to detect anti-PEG antibodies, minimizing false positives by ensuring that it does not react with other protein conjugates.
- The new assay demonstrated high sensitivity and specificity, successfully identifying anti-PEG antibodies in a healthy population, with robust validation showing low variability in results.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!